Balyasny Asset Management
ZYME icon

Balyasny Asset Management’s Zymeworks ZYME Stock Holding History

Balyasny Asset Management’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-50,000
Closed -$2.33M – 1776
2020
Q3 		$2.33M Buy
+50,000
New +$1.72M 0.02% 798

Other funds holding ZYME

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Balyasny Asset Management's ZYME Position: Q2 2023 in Review

Balyasny Asset Management sold out of Zymeworks (ZYME) in Q2 2023, closing a stake of 57,078 shares — an estimated $516K sold.

Balyasny Asset Management first reported a position in ZYME in Q3 2018 and held it in 3 quarters. The position peaked at $1.57M in Q3 2020. 137 funds tracked by Wall St. Rank hold ZYME as of Q2 2023.

  • Balyasny Asset Management reported no remaining Zymeworks position as of Q2 2023 after selling out during the quarter.
  • Balyasny Asset Management sold 57,078 Zymeworks shares in Q2 2023, an estimated $516K.
  • Balyasny Asset Management first reported a position in Zymeworks in Q3 2018 and held it in 3 quarters.
  • Balyasny Asset Management's Zymeworks position peaked at $1.57M in Q3 2020.
  • 137 funds tracked by Wall St. Rank held Zymeworks as of Q2 2023.

Based on Balyasny Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.